Research published today has highlighted potential growth down the line in the transdermal drug delivery patch space.
Kuick Research published an analysis claiming that the U.S. transdermal patch drug market is revolving on account of two powerful “mega-trends.” Those trends — acceleration in the U.S. pharmaceutical market growth and the restructuring of the healthcare sector to modulate drug delivery mechanisms more efficiently — could promote major growth in the next five years, according to a news release.
The researchers project that the market presents a $6 billion opportunity by 2026 as painless and non-invasive drug delivery methods become more and more sought after and cost-effectiveness and efficiency rise within the drug delivery and pharmaceutical space.
Kuick said the market has already experienced decades of “respectable” growth within a large market size, while it also presents promising business models that offer adaptability to patients.
Growing amounts of resources and technologically-driven innovations are only contributing to the rise of the market, researchers say, as they claim the transdermal patch space is a “constructive sector” for the entire U.S. pharmaceutical market.
The research concludes that, given the factors driving transdermal drug delivery, the overall market in the U.S. can be seen as a “dominant leader” over several decades to come.